Abpro Holdings, Inc. ABPO
0.44 USD -0.09 (-16.96%)
Nov 5, 2026, 1:33 PM EST
0.4401 Day range 0.50
0.087 52-week range 7.34
- YTD
- -89.60%
- 1 year
- -92.07%
- Market cap
- 2.59M
- EPS (ttm)
- 1.81
- P/E ratio
- 0.24
- YTD return
- -89.60%
- 1-year return
- -92.07%
- Volume
- 1.72K
- Avg volume
- 16.19K
- Open
- 0.445
- Previous close
- 0.53
- Day's range
- 0.4401 – 0.50
- 52-week range
- 0.087 – 7.34
1M +0.0401 (+10.02%)
Financials — quick view
ABPO Revenue — quarterly 0
ABPO Net income — quarterly -1.66M
ABPO EPS — quarterly -0.63
News
Short Interest in Abpro Holdings Inc. (NASDAQ:ABP) Increases By 271.4% 
Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference 
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 
Abpro (NASDAQ:ABP) Stock Price Up 0.2% – Still a Buy? 
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers 
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives 
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager 
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 
Abpro Holdings Inc. (NASDAQ:ABP) Sees Large Decrease in Short Interest 
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
Your note
Sign in to keep a note on ABPO — it syncs with the Stock Master app.